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Abstract
Background: Three main genes are described as causative genes for early-onset Alzheimer dementia (EOAD): APP,
PSEN1 and PSEN2. We describe a woman with EOAD had a novel PSEN1 mutation.
Case presentation: A 54-year-old right-handed woman presented 12-year history of progressive memory decline.
She was clinically diagnosed as familial Alzheimer's disease due to a PSEN1 mutation.
One of two daughters also has the same mutation, G209A in the TM-IV of PS1 protein. Her mother had unspecified
dementia that began at the age of 40s. PolyPhen2 and SIFT prediction suggested that G209A might be a damaging
variant with high scores. 3D modeling revealed that G209A exchange could result significant changes in the PS1 protein.
Conclusion: We report a case of EOAD having probable novel PSEN1 (G209A) mutation verified with structural prediction.
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Background
Alzheimer’s disease (AD) is the most common form
of senile dementia, which could usually occur in pa-
tients over 60 years old. AD occurring at younger
ages (early onset AD, EOAD) was quite rarely re-
ported (5-10 % of all AD cases). Genetic background
of EOAD was well-defined with three main genes:
amyloid precursor protein (APP), presenilin1 (PSEN1)
and presenilin2 (PSEN2). PSEN1, located on chromo-
some 14, was described as the most common causa-
tive gene for EOAD, due to the current
reports of more than 200 pathogenic mutations (AlzGene,
www.alzgene.org). Majority of these mutations were asso-
ciated with positive family history with autosomal dom-
inant inheritance pattern. Several de novo EOAD
cases were also reported, where no additional affected
family members was found. The age of disease onset,
associated with PSEN1 mutations, could be variable,
and the most of the cases occurred at age of onset at
40–50 years old [1].
In this manuscript, we report a novel PSEN1
G209A mutation in an EOAD patient. This mutation did
not exist in any of the AD mutation databases, and it
could be a novel causative mutation for EOAD.
Case presentation
A 54-year-old right-handed woman presented 12-year
history of progressive memory decline. She was a univer-
sity educated woman. At the age of 42 years, her main
symptoms were that she forgot names and needed to
make notes. She had poorer recall of information than
the others at her school of hotel management. In con-
trast, she was independent in all activities of daily living
but her mood was depressed. At initial consultation,
when she was 45 years old, general neurological exam
was unremarkable. Attention, language and visuospatial
function and frontal executive function were normal.
Apraxia, dyscalculia and Gerstmann syndrome were not
shown. However, Hopkin’s verbal learning test showed
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that free-recall score was 21 (5-8-8) and 20 min delayed-
recall was 2. Its recognition score presented that true
positive was 8 and false positive was 3. Delayed recall of
Rey figure score was 5.5. Mini-Mental State Examination
(MMSE) was 27/30, time orientation 4/5 and three word
recall 2/3. Magnetic Resonance Imaging (MRI) scan are
shown in Fig. 1a. The upper axial and coronal FLAIR
images showed that medial temporal lobe atrophy was
not prominent but bilateral parietal atrophy was on. Her
APOE genotype was homozygous for ε3. Her mother
had dementia at the age of 40s and died before 60s. No
specific diagnosis was made in her mother. Her father
and only brother did not show dementia. She has two
daughters, 29 and 26 years old. The initial clinical im-
pression was mild cognitive impairment with depression.
However, AD could not be ruled out. She showed
progressive deterioration in verbal and visual memory.
At the age of 53, her MMSE was 2/30 and clinical
dementia rate (CDR) was 3. She was able to respond
only to her name and distinguish her daughter from
unfamiliar people. She needed personal care. Her
brain MRI (Fig. 1a, lower) demonstrated that global
cortical atrophy, more prominent in medial temporal
and parietal lobes. FDG-PET (fludeoxyglucose- posi-
tron emission tomography) of the patient reveals the
bilateral temporal, parietal, precuneal and frontal
hypometabolism (Fig. 1b). They consent to perform gen-
etic sequencing on her and her 2 daughters. We screened
the APP, PSEN1, PSEN2 and PRNP (prion protein) gene.
Genetic analysis of PSEN1 and structural prediction of
mutant PSEN 1 protein
Methods
White blood cells (or buffy coat) were separated by cen-
trifugation at 800 g (30 minutes). Genomic DNA was ex-
tracted by GeneAll blood kit (Seoul Korea) as described
in the protocol. We performed a polymerase chain reac-
tion (PCR)-based genetic analysis. We used PCR primers
for APP exon 16 [2] and 17 [3], PSEN1 exon 4, 5, 6, 7, 8
and 11 [4, 5], PSEN2 exon 4, 5, 6, 7 and 12 [4] and PRNP
genes [6]. Single-strand conformation polymorphism
(SSCP, Fig. 2a) analysis was performed with the PCR prod-
ucts. Denaturation buffer was added to the amplicons
(50:50), which was composed of 95 % formamide, 18mMol
Fig. 1 a Axial and coronal FLAIR images of brain MRI. The upper images at the age of 48 show that bilateral parietal atrophy (empty arrow). The
lowers at the age of 54 show that diffuse cortical atrophy and prominent atrophic change in medial temporal (arrow head) and bilateral parietal
lobes (filled arrow). b Statistical parametric maps (11 age matched control subjects; p < 0.001, uncorrected; extent threshold = 50 voxels) of
FDG-PET of the patient, which reveal the bilateral temporal, parietal, precuneal and frontal hypometabolism. The color scale of statistical parametric
maps indicates the Z value magnitude, with the lowest value appearing in dark red and the highest value in bright yellow/white
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EDTA and 0.025 % xylene cyanol, and bromophenol
blue. These mixes were incubated on 98 °C for 10 mi-
nutes, resulting in the denaturation of double stranded
DNA bands [7]. The single stranded DNA bands were
separated in non-denaturing polyacrylamide gel electro-
phoresis (PAGE) (10-12 %) for 18–21 hours (BioRAD,
Seoul, Korea). Depending on the mutations, single
stranded DNAs could have different mobility in the gel.
SYBR Gold staining (Invitrogen, USA) was used for
staining DNA bands, which visualized under UV light.
To confirm and identify the mutation, sequencing was
performed for all PCR products at both directions by
the BioNeer Inc. (Dajeon, Korea). Prior to sequencing,
we purified the PCR products by GeneAll PCR protocol
kit (Seoul, Korea), as described in the protocol. For the se-
quencing reactions, Big Dye Terminator Cyclic sequencing
was performed on ABI 3730XL DNA Analyzer (http://
eng.bioneer.com/home.aspx, Bioneer Inc., Dajeon, Korea)
was used (Fig. 2 b and c). We aligned the sequenceing re-
sults by NCBI Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi),
and the chromatograms were analyzed by DNA
BASER (http://www.dnabaser.com) software. Muta-
tions and sequence variants were identified by using
the NCBI Gene (http://www.ncbi.nlm.nih.gov/gene)
and UniProt (http://www.uniprot.org) databases.
Mutations were analyzed by an online software, the
Polymorphism Phenotyping v2 (PolyPhen 2, http://
genetics.bwh.harvard.edu/pph2/), which could make in
silico predictions on the putative damaging properties of
mutations. This software made a comparison on the
wild-type and mutant alleles of proteins by homology
searching and multiple sequence alignment. Identity-
and structure-based searches, such as accessible surface
area and hydrophobicity features, were also performed.
These predictions might define the potential role of
amino acid exchanges in the proteins. Three catego-
rized of mutations could be available: probably,
possibly damaging or benign variants. PolyPhen2 could
also provide a multiple sequence alignment, by comparing
the homologous sequences from different vertebrate and
non-vertebrate species. Two types of datasets could be
available: the HumDiv and HumVar scores. HumDiv
should be used for the prediction of putative pathogenic
nature of rare alleles. In HumDiv scores, the alleles with
mildly damaging properties should be categorized as pos-
sibly damaging. HumVar should be used in case of diagno-
sis of Mendelian disorders. Here, the highly damaging
phenotypes should be distinguished from the alleles with
less damaging phenotypes [8].
Sorting Intolerant from Tolerant or SIFT algorithm
(http://sift.jcvi.org/) is an online software, which esti-
mates the potential effects of missense mutations sub-
stitution on the protein function. SIFT uses several
protein databases, including SWISS-PROT, SWISS-
PROT/TrEMBL, or protein databases of NCBI, and
calculates the possibility on the damaging nature of
mutations by the comparison of the mutant and nor-
mal proteins. It scores the amino acid substitutions,
and under and over the score of 0.05, mutations
could be defined as deleterious or tolerated, respect-
ively diction [9].
3D structures of PS1 with mutation(s) were ana-
lyzed by an online software, the Raptor X (http://rap-
torx.uchicago.edu/, Fig. 3). Server of protein structure
prediction used the full amino acid sequence of PS1
(1–467 amino acids). Discovery Studio 3.5 Visualizer
from Accelrys was used to display the images after
superimposition [10].
Results
Alternative mobility was found in the SSCP (Fig. 2a) for
exon 7 of PSEN1 gene. Sequencing revealed a G→ C ex-
change at codon 209, resulting in a glycine (GGA)→
Alanine (GCA) exchange (Fig. 2b and c). This mutation
Fig. 2 a SSCP data for PSEN1 G209A. Sample was verified as negative for any mutation in PSEN1 exon7. P*, proband; D1*, affected daughter; D2,
unaffected daughter; C, control sample. b Sequencing data of EOAD patient with PSEN1 G209A and location of G209A in PSEN1
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was not found in neither in the AD and FTD muta-
tion database nor in the Alzgene database, which sug-
gested that it might be a novel mutation in PSEN1.
Mutation was checked in the Exome Aggregation
Consortium (ExAC) database, which screened 60,706
unrelated individuals for the different disease causing
genes (http://exac.broadinstitute.org/). PSEN1 G209A
was not found in this database.
PolyPhen-2 scores were high, both HumDiv and
HumVar was 1.000 (sensitivity: 0.00; specificity: 1.00
at both scores) suggesting G209A as a probably dam-
aging variant. Multiple sequence alignment suggested
that glycine 209 might be a conservative residue
among vertebrates. Several mammalian (such as dogs,
pigs) and non-mammalian (such as chicken, frog, zeb-
rafish) showed glycine at the same position in their
presenilin or presenilin-like proteins. SIFT prediction
also confirmed the probably damaging nature of mu-
tation, with the score of 0.
3D prediction (Fig. 3) revealed significant differences
in the N-terminal region of normal PS1 protein. The c-
terminal region of normal PS1 and PS1 with G209A
were overlapped. These findings suggest that even
glycine and alanine are both small sized, hydrophobic
amino acids, but one extra –CH3 group on alanine
could result significant differences in the protein struc-
ture. Since alanine is more hydrophobic than glycine, it
could result extra stress inside the helix.
Discussion
We reported a novel mutation in PSEN1, the G209A in
a female patient in her early 50s. Even though we could
not find any affected family members, one of her daugh-
ters is a mutation carrier and deceased mother had an
undiagnosed case of dementia. Our finding suggested
that this mutation could be a novel probably pathogenic
variant, involved in EOAD.
Glycine 209 is located in the transmembrane –IV re-
gion of PS1 protein, and it was suggested as a conserva-
tive residue. For codon 209, three additional mutations
were found, G209R, G209E and G209V (Table 1), which
also suggested that Glycine 209 might be an important
residue in PS1. G209R was found in a Japanese family.
The proband was a male patient, the disease progression
started at the age of 46. Additional affected family
Fig. 3 3D model modeling for PS1 G209A. Differences of normal and mutant PSEN1 have been highlighted in the black circle, and glycine was
labeled with yellow, while alanine was labeled with yellow. The C-terminal pert of normal and abnormal proteins were overlapped, while signifi-
cant differences could be seen in the N-terminal part, suggesting that the mutation could result significant conformational changes in the TM
structure of PSEN1. a Differences between normal PSEN1 and PSEN1 G209A, focused on all over the protein. b Differences between normal and
mutant PSEN1, focused on the TM-IV region.
Table 1 Comparison of G209R, G209E, G209V and G209A
Mutation Gly209Arg Gly209Glu Gly209Val Gly209Ala
Age of onset 46 – 53 years unknown 30 - 48 years 54 years
Age of death unknown unknown unknown Surviving
Family history positive Unknown
(detected in 1 patient)
positive Unknown (since her mother had
undiagnosed early-onset dementia)




change, but lacking parietal
focal symptoms such as
apraxia or agnosia
unknown AD with myoclonus, seizures,
language loss, aphasia
Mild cognitive impairment with
depression, followed by progressive
deterioration in verbal and visual
memory
Reference Sugiyama et al. 1999 [11] Rogaeva et al. 2001 [14] Poorkaj et al. 1998 [12]
Larner et al. 2006 [13]
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members were found, since his sister and mother also
showed clinical symptoms. All of these patients showed
rapid progression of dementia, with memory impair-
ment, amnesia, aphasia, disorientation and personality
changes. Parietal focal symptoms such as apraxia or ag-
nosia were not apparent in the patients [11]. G209V was
found in a German family, where the age of onset
ranged between 30–48 years. Clinical symptoms in-
cluded myoclonus, seizures, language loss and apraxia
and agnosia [12, 13]. G209E was reported in one AD pa-
tient by Rogaeva. No detailed information was found on
the disease age of onset or clinical phenotype of disease,
associated with G209E [14].
In silico modeling and the previously described mu-
tations for G209 could support that PSEN1 G209A
could be a novel causative mutation for AD. Glycine
and alanine are similar, both of them are small sized
hydrophobic amino acids. 3D prediction suggested
that in this mutation, a single extra –CH3 group
could result disturbances inside the PS1 protein. Since
alanine is more hydrophobic than glycine, it could en-
hance the stress inside the PS1 TM domain or be-
tween PS1 and its binding partners.
As conclusion, we suggest that G209A can be a novel,
probably pathogenic variant in PSEN1. Guerrio et al.
published an algorithm for the novel mutations in
PSEN1 and PSEN2. Several criteria were analyzed: such
as whether the mutation is segregates with the disorder
segregation; whether there are additional affected fam-
ily members; and whether additional mutations were
described for the screened residue [15]. PSEN1 G209A
was not found in the ExAC database, which could be a
strong evidence on its pathogenic nature. The add-
itional three, probably pathogenic mutations for the
glycine at position 209 (G209R, G209V and G209E) can
also enhance the importance of residue 209 in PSEN1
and the probably damaging nature of G209A. However,
the family history of patient could not be well-defined.
Her mother was a dementia patient, but it remained
undiagnosed, so it is unclear whether she is the carrier
of mutation. One of her daughter carried the mutation,
who might be in the pre-symptomatic stage of disorder.
Online predictions were suggested that PSEN1 G209A
mutation could be a probably deleterious variant.
Additional studies are needed on for this variant since
its pathogenic nature can’t rely on the in silico pre-
dictions only.
Conclusions
We suggest that G209A can be a novel, probably patho-
genic variant in PSEN1. Combination of clinical-, associ-
ation studies, prediction- and 3D modeling software can
enhance the estimation on the pathogenic nature of
novel variants.
Consent
Written informed consent was obtained from the legal
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